Skip to content
Pompe Disease News logo
  • About Pompe
    What is Pompe disease?
    Types
    Symptoms
    Causes
    Diagnosis
    Treatment options
    • Lumizyme
    • Nexviazyme
    • Pombiliti + Opfolda
  • News
  • Columns
    The Pompe Community Diaries – Anthony Wu
    Powering Through Pompe — Keara Engle
    Archived columns
    • On the Road to Pompe — Dwayne Wilson
  • Living with Pompe
    Adaptive clothing
    Living with Pompe disease
    ERT and enzyme stabilizers
    The ERT process
    Your daily routine with LOPD
    Adaptive equipment
    Late-onset Pompe disease
    Dwayne’s story
    Expert voice: Safe and effective exercise
    How is Pompe disease inherited?
    Pompe disease and diet
    Reproductive options
    Support groups and resources
    LOPD and respiratory health
    Mental health
    Pompe and fatigue
    Travel and LOPD
    Exercise and physical therapy
    Science behind treatment
    ERT challenges
    Navigating school and work
    Pompe prevalence
    Pompe disease progression
  • Pompe pathways
    ERT home infusions
    Therapeutic crossroads
    Tips for caregivers
    Maximizing doctor’s appointments
    Building an LOPD care team
    Financial planning with Pompe
    Work and Pompe
    Occupational therapy
    Pompe and pain
  • FAQs
  • Advocacy partners
  • What can we help you find today?

August 4, 2023 Columns by Dwayne Wilson

How my childhood prepared me for a life of Pompe disease advocacy

When I was a kid, I liked to build things with Legos and Lincoln Logs. I had Tinker Toys and Erector sets to build cars, cranes, buildings, and more. All of the blocks, bricks, and logs were of different sizes and shapes, and when they were put together, I had…

July 16, 2020 News by Hawken Miller

MDA’s Virtual Drug Development Meeting Brings Together Pompe Patients, Industry

The Muscular Dystrophy Association (MDA) held its first externally led Patient-Focused Drug Development (PFDD) meeting on Pompe disease earlier this week.  The July 13 virtual PFDD meeting allowed Pompe patients and…

February 20, 2020 News by Grace Frank

20 States and DC Screening Newborns for Pompe as Efforts Continue for More, MDA Says

Across the U.S., 20 states are now screening newborns for Pompe, the most recent neuromuscular disease added to a list of serious genetic disorders for which infants can be tested shortly after birth, advocacy officers at the Muscular Dystrophy Association (MDA) said. Washington is the latest to…

February 6, 2020 News by Grace Frank

MDA Leads in Efforts to Help Patients With Neuromuscular Diseases – From Care Centers to Research Grants and Summer Camp

Expecting to award roughly $18 million this year in grants to support research in neuromuscular diseases, the Muscular Dystrophy Association (MDA) continues to be a leader in efforts to better treat and otherwise ease life for those touched by Pompe disease as well as muscular dystrophy, and…

Recent Posts

  • Gene, enzyme replacement improve mice’s breathing, limb strength
  • Short-distance walking speed test in Pompe disease is less demanding
  • Nervous system involvement is common in Pompe disease: Study


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.